Arrowhead Pharmaceuticals: Phase 3 success with Plozasiran opens billion-dollar market
Reading Time: 3 minutes
Plozasiran achieves all primary and pre-defined secondary endpoints in SHASTA-3 and SHASTA-4, reducing triglycerides by 79% and 81% after twelve months. Acute pancreatitis events decrease by 78%, and by 100% in high-risk patients. Arrowhead sees a market opportunity in the USA with over 3 million sHTG patients compared to about 6,500 FCS patients previously. Arrowhead Pharmaceuticals (ARWR) has impressed over the past twelve months with a share price performance of over 327%, transforming from a research company into a commercial...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
